1. Home
  2. CSWC vs CRVS Comparison

CSWC vs CRVS Comparison

Compare CSWC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

SELL

Current Price

$23.12

Market Cap

1.6B

ML Signal

SELL

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$9.53

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSWC
CRVS
Founded
1961
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
CSWC
CRVS
Price
$23.12
$9.53
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$25.08
★ $33.14
AVG Volume (30 Days)
506.1K
★ 1.2M
Earning Date
11-02-2026
11-03-2026
Dividend Yield
★ 10.89%
N/A
EPS Growth
29.25
★ 48.04
EPS
★ 0.39
N/A
Revenue
★ $10,835,000.00
N/A
Revenue This Year
$14.86
N/A
Revenue Next Year
$13.58
N/A
P/E Ratio
$60.41
★ N/A
Revenue Growth
★ 16.08
N/A
52 Week Low
$19.91
$6.39
52 Week High
$25.75
$26.95

Technical Indicators

Market Signals
Indicator
CSWC
CRVS
Relative Strength Index (RSI) 39.39 30.01
Support Level $22.76 $6.39
Resistance Level $23.86 $13.73
Average True Range (ATR) 0.32 0.59
MACD 0.03 -0.06
Stochastic Oscillator 28.56 11.37

Price Performance

Historical Comparison
CSWC
CRVS

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source of revenue comprises interest income and dividend income from investments made as well as management fees.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: